BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17697207)

  • 1. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy.
    Palmieri O; Latiano A; Bossa F; Vecchi M; D'Incà R; Guagnozzi D; Tonelli F; Cucchiara S; Valvano MR; Latiano T; Andriulli A; Annese V
    Aliment Pharmacol Ther; 2007 Sep; 26(5):737-45. PubMed ID: 17697207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease.
    Van Dieren JM; Hansen BE; Kuipers EJ; Nieuwenhuis EE; Van der Woude CJ
    Aliment Pharmacol Ther; 2007 Sep; 26(5):643-52. PubMed ID: 17697198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q; Zhu Q; Shang Y; Gao M; Si J
    Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
    De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
    Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
    Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
    Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease.
    Jena A; Grover N; Bhatia P; Singh M; Lad D; Prasad KK; Singh H; Dutta U; Sharma V
    Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):25-30. PubMed ID: 36707393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
    Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
    Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
    Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
    Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
    Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR
    Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
    Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.
    Wroblova K; Kolorz M; Batovsky M; Zboril V; Suchankova J; Bartos M; Ulicny B; Pav I; Bartosova L
    Dig Dis Sci; 2012 Sep; 57(9):2394-401. PubMed ID: 22535280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.
    Herrlinger KR; Jewell DP
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1403-12. PubMed ID: 17081161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.